ASCO 2021 | SWOG S1216: ADT and TAK700 in prostate cancer

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, discusses the updated results of the SWOG S1216 trial (NCT01809691): a Phase III trial comparing the safety and efficacy of androgen deprivation therapy (ADT) and the 17,20-lyase inhibitor TAK-700 with ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). TAK-700 significantly reduced progression by 42% and led to better prostate-specific antigen (PSA) responses; 14% more patients achieved a complete response, compared to the bicalutamide group. However adverse events (AEs) were increased in the TAK-700 group and although the improvement in overall survival (OS) in the TAK-700 group, 11 months, was clinically significant, it was not enough to be considered statistically significant; the OS in the control group was the highest ever recorded in such a trial. These findings provide a new benchmark for survival estimates in future trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.